Should Biomarkers Be Used to Design Personalized Medicine for the Treatment of Glioblastoma?

• Yung WKA , AlbrightRE, OlsonJet al.: A Phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.Br. J. Cancer83, 588–593 (2000).
   PubMed Web of Science ®Google Scholar
• Stupp R , MasonWP, van den BentMJet al.: Radiotherapy plus concomitant and adjuvant temozolomide for patients with newly diagnosed glioblastoma.N. Engl. J. Med.352, 987–996 (2005).
   PubMed Web of Science ®Google Scholar
• Stupp R , HegiME, MasonWPet al.: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial.Lancet Oncol.10, 459–466 (2009).
   PubMed Web of Science ®Google Scholar
• Hegi ME , DiserensAC, GorliaTet al.: MGMT gene silencing and response to temozolomide in glioblastoma.N. Engl. J. Med.352, 997–1003 (2005).
   PubMed Web of Science ®Google Scholar
• Wick W , EngelC, CombsSEet al.: NOA-08 randomized Phase III trial of 1-week-on/1-week-off temozolomide versus involved field radiotherapy in elderly (older than age 65) patients with newly diagnosed anaplastic astrocytoma or glioblastoma (Methusalem).J. Clin. Oncol.28(7 Suppl.) (2010) (Abstract LBA2001).
   Google Scholar
• Grossmann SA , YeX, ChamberlainMet al.: Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter Phase II trial.J. Clin. Oncol.27, 4155–4161 (2009).
   PubMed Web of Science ®Google Scholar
• Stupp R , HegiME, NeynsBet al.: Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.J. Clin. Oncol.28, 2712–2718 (2010).
   PubMed Web of Science ®Google Scholar
• Wick A , FelsbergJ, SteinbachJPet al.: Efficacy and tolerability of temozolomide in an one week on/one week off regimen in patients with recurrent glioma.J. Clin. Oncol.25, 3357–3361 (2007).
   PubMed Web of Science ®Google Scholar
• Perry JR , BelangerK, MasonWPet al.: Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma.J. Clin. Oncol.28, 2051–2057 (2010).
   PubMed Web of Science ®Google Scholar
• The Cancer Genome Atlas Consortium: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061–1068 (2008).
   PubMed Web of Science ®Google Scholar
• Parsons DW , JonesS, ZhangXet al.: An integrated genomic analysis of human glioblastoma multiforme.Science321, 1807–1812 (2008).
   PubMed Web of Science ®Google Scholar
• Weller M , FelsbergJ, HartmannCet al.: Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma. A prospective translational study of the German Glioma Network.J. Clin. Oncol.27, 5743–5750 (2009).
   PubMed Web of Science ®Google Scholar
• Verhaak RG , HoadleyKA, PurdomEet al.: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.Cancer Cell17, 98–110 (2010).
   PubMed Web of Science ®Google Scholar
• Haas-Kogan DA , PradosMD, TihanTet al.: Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.J. Natl Cancer Inst.97, 880–887 (2005).
   PubMed Web of Science ®Google Scholar
• Mellinghoff IK , WangMY, VivancoIet al.: Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.N. Engl. J. Med.353, 2012–2024 (2005).
   PubMed Web of Science ®Google Scholar
• Van den Bent MJ , BrandesAA, RamplingRet al.: Randomized Phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC Brain Tumor Group study 26034.J. Clin. Oncol.27, 1268–1274 (2009).
   PubMed Web of Science ®Google Scholar
• Brandes AA , FranceschiE, TosoniA, HegiME, StuppR: Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments.Clin. Cancer Res.14, 957–960 (2008).
   PubMed Web of Science ®Google Scholar
• Heimberger AB , SampsonJH: The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients.Expert Opin. Biol. Ther.9, 1087–1098 (2009).
   PubMed Web of Science ®Google Scholar
• Jenkins RB , BlairH, BallmanKVet al.: A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma.Cancer Res.66, 9852–9861 (2006).
   PubMed Web of Science ®Google Scholar
• Cairncross JG , UekiK, ZlatescuMCet al.: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.J. Natl Cancer Inst.90, 1473–1479 (1998).
   PubMed Web of Science ®Google Scholar
• Cairncross G , BerkeyB, ShawEet al.: Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.J. Clin. Oncol.24, 2707–2714 (2006).
   PubMed Web of Science ®Google Scholar
• Van den Bent MJ , CarpentierAF, BrandesAAet al.: Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer Phase III trial.J. Clin. Oncol.24, 2715–2722 (2006).
   PubMed Web of Science ®Google Scholar
• Wick W , HartmannC, EngelCet al.: NOA-04 randomized Phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.J. Clin. Oncol.27, 5874–5880 (2009).
   PubMed Web of Science ®Google Scholar
• Jaeckle KA , EyreHJ, JeannetteJet al.: Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis- chloroethylnitrosourea: a Southwest Oncology Group study.J. Clin. Oncol.16, 3310–3315 (1998).
   PubMed Web of Science ®Google Scholar
• Weller M , StuppR, ReifenbergerGet al.: MGMT promoter methylation in malignant gliomas: ready for personalized medicine?Nature Rev. Neurol.6, 39–51 (2010).
   PubMed Web of Science ®Google Scholar
• Esteller M , Garcia-FoncillasJ, AndionEet al.: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.N. Engl. J. Med.343, 1350–1354 (2000).
   PubMed Web of Science ®Google Scholar
• Hegi ME , DiserensAC, GodardSet al.: Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.Clin. Cancer Res.10, 1871–1874 (2004).
   PubMed Web of Science ®Google Scholar
• Preusser M , JanzerRC, FelsbergJet al.: Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker.Brain Pathol.18, 520–532 (2008).
   PubMed Web of Science ®Google Scholar
• Grasbon-Frodl EM , KrethFW, RuiterMet al.: Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas.Int. J. Cancer121, 2458–2464 (2007).
   PubMed Web of Science ®Google Scholar
• Brandes AA , FranceschiE, TosoniAet al.: O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications.Neuro-Oncology12, 283–288 (2010).
   PubMed Web of Science ®Google Scholar
• Tonn J , FelsbergJ, ThonNet al.: MGMT promoter methylation status and DNA mismatch repair genes in paired primary and recurrent glioblastoma: a translational study of the German Glioma Network.J. Clin. Oncol.28(15 Suppl.) Abstr. 2076 (2010).
   PubMed Web of Science ®Google Scholar
• Zhao S , LinY, XuWet al.: Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1a.Science324, 261–265 (2009).
   PubMed Web of Science ®Google Scholar
• Dang L , WhiteDW, GrossSet al.: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.Nature462, 739–744 (2009).
   PubMed Web of Science ®Google Scholar
• Frezza C , TennantDA, GottliebE: IDH1 mutations in gliomas: when an enzyme loses its grip.Cancer Cell17, 7–9 (2010).
   PubMed Web of Science ®Google Scholar
• Yan H , ParsonsDW, JinGet al.: IDH1 and IDH2 mutations in gliomas.N. Engl. J. Med.360, 765–773 (2009).
   PubMed Web of Science ®Google Scholar
• Capper D , WeissertS, BalssJet al.: Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.Brain Pathol.20, 245–254 (2010).
   PubMed Web of Science ®Google Scholar
• Noushmehr H , WeisenbergerDJ, DiefesKet al.: Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.Cancer Cell17, 510–522 (2010).
   PubMed Web of Science ®Google Scholar
• Reya T , MorrisonSJ, ClarkeMF, WeissmanIL: Stem cells, cancer, and cancer stem cells.Nature414, 105–111 (2001).
   PubMed Web of Science ®Google Scholar
• Singh SK , HawkinsC, ClarkeIDet al.: Identification of human brain tumour initiating cells.Nature432, 396–401 (2004).
   PubMed Web of Science ®Google Scholar
• Clement V , MarinoD, CudalbuCet al.: Marker-independent identification of glioma-initiating cells.Nature Methods7, 224–228 (2010).
   PubMed Web of Science ®Google Scholar
• Son MJ , WoolardK, NamDH, LeeJ, FineHA: SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma.Cell Stem Cell4, 440–452 (2009).
   PubMed Web of Science ®Google Scholar
• Bao S , WuQ, McLendonREet al.: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.Nature444, 756–760 (2006).
   PubMed Web of Science ®Google Scholar
• Pallini R , Ricci-VitianiL, BannaGLet al.: Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme.Clin. Cancer Res.14, 8205–8212 (2008).
   PubMed Web of Science ®Google Scholar
• Schwartzbaum JA , HuangK, LawlerS, DingB, YuJ, ChioccaEA: Allergy and inflammatory transcriptome is predominantly negatively correlated with CD133 expression in glioblastoma.Neuro-Oncology12, 320–327 (2010).
   PubMed Web of Science ®Google Scholar
• Murat A , MigliavaccaE, GorliaTet al.: Stem cell-related ‘self-renewal’ signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.J. Clin. Oncol.26, 3015–3024 (2008).
   PubMed Web of Science ®Google Scholar
• Clement V , DutoitV, MarinoDet al.: Limits of CD133 as a marker of glioma self-renewing cells.Int. J. Cancer125, 244–248 (2009).
   PubMed Web of Science ®Google Scholar
• Griguer CE , OlivaCR, GobinEet al.: CD133 is a marker of bioenergetic stress in human glioma.PLoS One3, E3655 (2008).
   PubMed Web of Science ®Google Scholar
• Essers MA , OffnerS, Blanco-BoseWEet al.: IFNa activates dormant haematopoietic stem cells in vivo.Nature458, 904–908 (2009).
   PubMed Web of Science ®Google Scholar
• Weaver KD , GrossmanSA, HermanJG: Methylated tumor-specific DNA as a plasma biomarker in patients with glioma.Cancer Invest.24, 35–40 (2006).
   PubMed Web of Science ®Google Scholar
• Wakabayashi T , NatsumeA, HatanoHet al.: p16 promoter methylation in the serum as a basis for the molecular diagnosis of gliomas.Neurosurgery64, 455–461 (2009).
   PubMed Web of Science ®Google Scholar
• Liu BL , ChengJX, ZhangWet al.: Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas.Neuro-Oncology12, 540–548 (2010).
   PubMed Web of Science ®Google Scholar
• Balaña C , RamirezJL, TaronMet al.: O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme.Clin. Cancer Res.9, 1461–1468 (2003).
   PubMed Web of Science ®Google Scholar
• Lavon I , RefaelM, ZelikovitchBet al.: Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades.Neuro-Oncology12, 173–180 (2010).
   PubMed Web of Science ®Google Scholar
• Tanwar MK , GilbertMR, HollandEC: Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma.Cancer Res.62, 4364–4368 (2002).
   PubMed Web of Science ®Google Scholar
• Johansen JS , Vittrup JensenB, RoslindAet al.: Serum YKL-40, a new prognostic biomarker in cancer patients?Cancer Epidemiol. Biomarkers Prev.15, 194–202 (2006).
   PubMed Web of Science ®Google Scholar
• Hormigo A , GuB, KarimiSet al.: YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas.Clin. Cancer Res.12, 5698–5704 (2006).
   PubMed Web of Science ®Google Scholar
• Batchelor TT , SorensenAG, di TomasoEet al.: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastomas patients.Cancer Cell11, 83–95 (2007).
   PubMed Web of Science ®Google Scholar
• Sorensen AG , BatchelorTT, ZhangWTet al.: A ‘vascular normalization index’ as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.Cancer Res.69, 5296–5300 (2009).
   PubMed Web of Science ®Google Scholar
• Gartner W , IlhanA, NeziriDet al.: Elevated blood markers 1 year before manifestation of malignant glioma.Neuro-Oncology DOI: 10.1093/neuonc/noq034 (2010) (Epub ahead of print).
   Google Scholar
• Lawler S , ChioccaEA: Emerging functions of microRNAs in glioblastoma.J. Neurooncol.92, 297–306 (2009).
   PubMed Web of Science ®Google Scholar
• Ludwig N , KellerA, HeiselSet al.: Improving seroreactivity-based detection of glioma.Neoplasia11, 1383–1389 (2009).
   PubMed Web of Science ®Google Scholar
• Shnaper S , DesbailletsI, BrownDAet al.: Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome.Int. J. Cancer125, 2624–2630 (2009).
   PubMed Web of Science ®Google Scholar

Website

• European Organization for Research and Treatment of Cancer www.eortc.be
   Google Scholar